Regeneron Pharmaceuticals, Inc.
Methods of treating eosinophilic esophagitis by administering an antibody which inhibits interleukin-4 receptor (IL-4R)

Last updated:

Abstract:

The present invention provides methods for treating, preventing or reducing the severity of eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R.alpha.) inhibitor such as an anti-IL-4R.alpha. antibody.

Status:
Grant
Type:

Utility

Filling date:

24 Jun 2020

Issue date:

23 Aug 2022